According to statistics from the Office for Life Sciences, interventional clinical trials in 2023-2024 featured 19,984 participants – a 9.2% reduction compared to the same time frame in 2022-2023.

Moderna, a US-based biopharmaceutical company with an expertise in messenger RNA (mRNA), has announced updates in the two years since it signed a ten-year partnership with the UK Government.

The University of Sheffield, UK, has announced study results for its trial into the survival rates of patients with operable bladder cancer, finding that those who have immunotherapy before and after the surgery have significantly improved rates of survival.

The European Commission (EC) has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small-to medium-sized enterprises (SMEs) in bringing new innovations to the EU market.

Biotech company Cytomos has announced this month that it has raised £5m to scale up the production of its unique cell analysis technology.

Advance Tests, committed to enhancing diagnostic accessibility and advancing early disease detection, announced the exclusive UK launch of LucentAD complete.

Risk-based quality management (RBQM) and data quality oversight software company Cluepoints launches its latest application, the medical & safety review (MSR), to simplify and streamline the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history.

Liquid biopsy company ANGLE plc has announced a partnership with NuProbe, a genomics and molecular diagnostics company, to utilise the latter’s pan-cancer next-generation sequencing (NGS) panel.

Earlier this September, the US Food and Drug Administration (FDA) granted approval for PureTech Health’s Karxt for the treatment of schizophrenia in adults, triggering royalty payments of $29m to PureTech. It will be the first approved mechanism by the FDAfor schizophrenia in over 50 years.

Owlstone Medical has entered into a research collaboration with the US Food and Drug administration’s (FDA) centre for devices and radiological health to develop methods for the confident identification of individual chemicals in the composure of breath.

Ars pharmaceuticals has been granted approval by the us food and drug administration (fda) for their epinephrine nasal spray, neffy, to be used as treatment of type 1 allergic reactions including anaphylaxis.

Leading life science investor novo holdings has announced a £50m investment in oxford nanopore technologies. Oxford nanopore technologies is a leading uk-listed company currently specialising in a new generation of molecular sensing technology based on nanopores.